Wolverine Trading’s Inovio Pharmaceuticals INO Stock Holding History

Wolverine Trading’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-12,161	Closed	-$53.8K	–	5547
2024 Q3	$71.3K	Sell	12,161 -2,646	-18%	-$21.8K	﹤0.01%	4450
2024 Q2	$120K	Buy	+14,807	New	+$156K	﹤0.01%	4020
2024 Q1	–	Sell	-840	Closed	-$5.14K	–	4852
2023 Q4	$5.14K	Buy	+840	New	+$4.15K	﹤0.01%	4415
2022 Q4	–	Sell	-1,474	Closed	-$33.4K	–	4461
2022 Q3	$30K	Buy	+1,474	New	+$37.7K	﹤0.01%	4297
2022 Q1	–	Sell	-1,408	Closed	-$63.4K	–	5874
2021 Q4	$88K	Buy	+1,408	New	+$113K	﹤0.01%	5145
2021 Q2	–	Sell	-3,733	Closed	-$359K	–	6336
2021 Q1	$395K	Buy	3,733 +2,091	+127%	+$275K	﹤0.01%	4069
2020 Q4	$177K	Buy	+1,642	New	+$219K	﹤0.01%	4295
2020 Q3	–	Sell	-1,233	Closed	-$469K	–	4833
2020 Q2	$469K	Buy	+1,233	New	+$198K	﹤0.01%	2802

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's INO Position: Q4 2024 in Review

Wolverine Trading sold out of Inovio Pharmaceuticals (INO) in Q4 2024, closing a stake of 12,161 shares — an estimated $53.8K sold.

Wolverine Trading first reported a position in INO in Q2 2020 and held it in 8 quarters. The position peaked at $469K in Q2 2020. 104 funds tracked by Wall St. Rank hold INO as of Q4 2024.

Wolverine Trading reported no remaining Inovio Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Wolverine Trading sold 12,161 Inovio Pharmaceuticals shares in Q4 2024, an estimated $53.8K.
Wolverine Trading first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Wolverine Trading's Inovio Pharmaceuticals position peaked at $469K in Q2 2020.
104 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2024.

Based on Wolverine Trading's 13F filing for Q4 2024, filed 14 Feb 2025.